Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2018

View Archived Issues

Messenger RNA can treat porphyria

Neurons can switch transmitter allegiance in vivo

Astellas Cathespin S inhibitors prolong graft survival in a mouse cardiac transplant model

Targeted cancer therapy leads to twist of cell fate

Brigham Young University patents therapeutic bacteriophages

[18F]FC-303, an 18F-labeled PSMA radiotracer for PET imaging of prostate cancer

Shanghai De Novo Pharmatech identifies Wee1-like protein kinase inhibitors

Hefei Amvite Pharmaceutical and collaborators identify platelet adhesion inhibitors

SQZ Biotech expands cellular therapy partnership with Roche

Phase I/II study of KB-103 meets all primary efficacy and safety endpoints at interim data analysis

Soligenix receives recommendation to continue phase III FLASH study of SGX-301

TherapyX and Intravacc partner to develop Ngoxim prophylactic vaccine against gonorrhea

Cellect reports promising data from phase I/II study of ApoGraft technology

Dupixent reduces nasal polyp size and nasal congestion severity in phase III trials

[18F]HTK-01174 shows promise for PET imaging of prostate cancer

BARDA funding to support pediatric studies of Stratagraft for thermal burns

NIH grant supports Allele's development of nanoantibodies to treat sepsis

Praliciguat shows promise in phase IIa study in patients with type 2 diabetes and hypertension

Studies evaluate autologous tolerogenic dendritic cells in multiple sclerosis patients

ADAMTS7 as indicator of early left ventricular diastolic and systolic dysfunction in type 2 diabetes

VenatoRx presents pharmacokinetic and safety data for VNRX-5133

Inherited polymorphisms contribute to increased risk for Waldenstrom macroglobulinemia

Liposome adjuvant increases the immunogenicity of malaria vaccines

OncoSec initiates KEYNOTE-890 phase II study of Tavo plus Keytruda for TNBC

Athenex reports initial pilot results for T-cell receptor affinity enhancing specific T-cell therapy

Restorbio reports additional phase IIb data on RTB-101

FDA clears IND for phase I trial of CK-0801 in treatment-resistant Guillain-Barre syndrome

Axsome to develop AXS-12 for narcolepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...